BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25697914)

  • 1. Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the (18)F-fluorodeoxyglucose-positron emission tomography era.
    Gonçalves Mde C; de Paula HM; Linardi Cda C; Cerci JJ; Aldred VL; Siqueira SA; Buccheri V; Zerbini MC
    Leuk Lymphoma; 2015; 56(10):2883-8. PubMed ID: 25697914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.
    Moulin-Romsee G; Hindié E; Cuenca X; Brice P; Decaudin D; Bénamor M; Brière J; Anitei M; Filmont JE; Sibon D; de Kerviler E; Moretti JL
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1095-105. PubMed ID: 20204358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era.
    Richardson SE; Sudak J; Warbey V; Ramsay A; McNamara CJ
    Leuk Lymphoma; 2012 Mar; 53(3):381-5. PubMed ID: 21877882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of FDG-PET and bone marrow examination in lymphoma staging.
    El-Najjar I; Barwick T; Avril N; Montoto S
    Ann Oncol; 2012 Sep; 23 Suppl 10():x89-91. PubMed ID: 22987999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
    El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
    J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
    Adams HJ; Nievelstein RA; Kwee TC
    Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients.
    Chen-Liang TH; Martin-Santos T; Jerez A; Senent L; Orero MT; Remigia MJ; Muiña B; Romera M; Fernandez-Muñoz H; Raya JM; Fernandez-Gonzalez M; Lancharro A; Villegas C; Carlos Herrera J; Frutos L; Luis Navarro J; Uña J; Igua C; Sanchez-Vaño R; Cozar Mdel P; Contreras J; Sanchez-Blanco JJ; Perez-Ceballos E; Ortuño FJ
    Am J Hematol; 2015 Aug; 90(8):686-90. PubMed ID: 25925613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
    J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography-computed tomography era: a West of Scotland study.
    Hamilton R; Andrews I; McKay P; Leach M
    Leuk Lymphoma; 2014 May; 55(5):1049-52. PubMed ID: 23915196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
    Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.